Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jianjiao Ni"'
Autor:
Yuan Li, Zhengfei Zhu, Yang Zhao, Wanqin Zeng, Xiao Chu, Jianjiao Ni, Tiantian Guo, Wen Yu, Liqing Zou, Shengping Wang, Q. Liu, Yue Zhou, Yida Li, Luxi Ye, Ya Zeng, Li Chu, Shuyan Li, Xi Yang, Fan Yu
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:804-815
Purpose As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant
Autor:
Yuan Li, Zhengfei Zhu, Yida Li, Xi Yang, Xiao Chu, Jianjiao Ni, Luxi Ye, Li Chu, Shengping Wang, Shuyan Li, Tiantian Guo, Q. Liu, Liqing Zou
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 107:62-71
Purpose Despite the impressive response rate to osimertinib, acquired resistance remains an obstacle to achieving long-term tumor control in metastatic epidermal growth factor receptor–mutant non-small cell lung cancer. Stereotactic body radiation
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e422
PURPOSE/OBJECTIVE(S) Several PD-1/PD-L1 inhibitors have been approved, with or without chemotherapy, in advanced non-small cell lung cancer (NSCLC). However, the objective response rate (ORR) remains limited in unselected population. Accumulating dat
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:S175
Publikováno v:
Transl Lung Cancer Res
Background Our previous dosimetric study showed that for locally advanced non-small cell lung cancer (LA-NSCLC), radiotherapy with intensity-modulated radiotherapy (IMRT) technique could deliver sufficient dose coverage to subclinical regions and red
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:e751